Kalaris Therapeutics, Inc. reported improved Q3'25 results, with a net loss of $11.9M and $77M in cash. Click here to read why KLRS stock is a Buy.

Kalaris Therapeutics offers differentiated approach to neovascular AMD with its lead candidate TH103. Click here to read my ...

The FDA approved Nufymco as an interchangeable biosimilar to Lucentis, making it the second approved ranibizumab biosimilar ...

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive ...

George Gibson remembers turning to his wife after a 2015 procedure at a Florida clinic that he thought would help his failing eyesight. At the hotel room where they were staying, he went to open his ...

A clinical trial is investigating whether a stem cell-derived patch can replace disease-damaged cells and restore vision. Age-related macular degeneration is a steadily worsening eye disease and the ...

A data monitoring committee recommended stopping the phase 3 trials of efgartigimod in thyroid eye disease due to lack of efficacy.

With the other premium services, you can dive deep into additional metrics, portfolios, commentary and information about ...

Cataracts are one of the most common eye conditions worldwide and a leading cause of gradually declining vision in adults. Although often associated with aging, they can develop earlier in life and ...

I'm a Fitness & Nutrition writer for CNET who enjoys reviewing the latest fitness gadgets, testing out activewear and sneakers, as well as debunking wellness/fitness myths. In my free time I enjoy ...